CytoAgents is a clinical-stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID19, influenza, and other viral infectious diseases.
Using a novel, host-directed approach, we target the underlying cause of life- threatening symptoms associated with influenza and cytokine release syndrome by modulating the natural immune response to the disease. We are committed to developing “first-in-class, best-in-class” products that meet a major medical need.
Out platform targets respiratory epidemics such as Influenza, COVID19, and debilitating conditions such as Acute Respiratory Distress Syndrome. All of these cause severe inflammation triggered by the body’s immune response. While most treatments on the market today try to stop the onset of the disease, CytoAgents works to stop the progression of the symptoms and the associated mortality and morbidity.
By managing this response, patient outcomes will improve, resulting in less severe illness and deaths. Overall, society will benefit from of a reduction in fear, healthcare costs, and negative impact on the global economy.
We have built a world-renowned scientific advisory board, incorporating leading experts in the fields of infectious disease, virology, and immunology.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2018
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was CytoAgents founded?
CytoAgents was founded in 2018.
What industry is CytoAgents in?
CytoAgents operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is CytoAgents based?
CytoAgents is headquartered in Pittsburgh, United States.
Find investors for your startup like CytoAgents
Gritt sends AI-personalised outreach to each investor — from your Gmail